click enter text
trade fundament data
upsid target
full postview good anoth beat rais
report financi result morn revenu
ep beat consensu rais guidanc
first time report skyrizi sale beat consensu gave
impress full year guidanc
estim go modestli rais pt slightli vs
bodi report full analysi
recent in-depth discuss abbv pipelin see recap
addit detail us/eu drug
compani cover see recent report
juli issu monthli controversi report
factset/wolf research price
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
friday open
report result beat revenu ep
rais revenu growth increas ep rang
overal impress report set good quiet result continu legaci guid
conserv beat also rais guidanc year term news flow littl new
materi investor call question pend mega-d allergan
rather question dealt abbv base busi upcom pipelin event real one note
pend approv jak inhibitor upadacitinib ask investor reaction
transact see share sinc news claim drop in-lin rel
prior big deal arb pressur mostli blame ceo gonzalez said investor
met seem understand support transact understand long felt big deal
sort necessari solut pend entri us humira biosimilar ask
twice opioid litig exposur due prior co-market agreement pursu pharma flat
claim liabil exposur previous verbal relay us indemnifi purdu
question period come may happen purdu file bankruptci recal upgrad
under-perform peer perform follow deal announc upgrad
under-perform peer perform follow pull back share price felt downsid case longer
layer partli combin compani revenues/ep flat
improv sharp ep declin howev catalyst-
lite stori thin pipelin growth still uncertainti model us biosimilar
eros humira felt would difficult stock outperform peer base see today
arguabl low valuat name high dividend yield stabl long-term base real ep
concern next sever year valu investor may screen attract
recent in-depth discuss pipelin see recap pipelin unplug call w/chief
addit detail us/eu drug compani cover see juli
issu monthli controversi report
term sale ep exhibit
revenu report sale vs consensu
ep report non-gaap ep vs consensu
humira sale vs consensu remind second full quarter
biosimilar impact reflect abbv financi result
imbruvica sale vs consensu
hcv sale vs consensu
venclexta sale vs consensu
page
revenu rais oper fx previou flat y/i fx
humira guid y/i increas us ex-u sale cer
signal y/i decreas oper quarter
ep rais vs prior mid-point
pipelin disclos anti-tau agent termin rare diseas progress
revenu increas ep increas
revenu estim chang ep estim chang
depend year
ep compound-annual-growth-rate ep compound-annual-growth-rate increas slightli vs prior repres
peer averag growth peer average compound-annual-growth-rate rang admittedli drag
humira goe loe way longer relev pend acquisit
exhibit later report impact pro-forma basi
price target increas slightli repres unchang multipl new
ep estim price target impli price-to-earnings multipl approxim pro-forma abbv agn
revenu growth expect humira growth hem/onc rev imbruvica sale
skyrizi hcv approach split evenli us intenational orlissa admit
launch ramp slower expect
expect ep rev us humira intenational imbruvica
 declin sequenti say last gm perform right
line expect simpli quarter quarter variat
page
 abbv share price sinc deal announc investor
appreci say often happen big deal announc share
rose initi road investor met mostli posit impress arb
pressur part problem think stock perform differ expect
realli know investor view transact deal close short gone
bring great set asset
 updat potenti divestitur say want divest anyth ftc may ask
certain asset divest respect skyrizi would expect issu
 might biosimilar enbrel impact humira launch expect would impact
patient well control humira biosimilar remicad impact either us eu
impact would nave patient manag
 updat think eros curv us onward say
knowabl far abl later higher level confid certainli
intern base case eros curv updat year note made revis
assum acceler eros versu prior assumpt flatten first year
launch mirror eu experi seem shape blunt say
premis transact
launch go extrem well commerci access track in-lin expect expect full year sale
maintain muti-billion dollar peak sale potenti
 manag guid sale would nomin fact strong go
say prescrib market recept product due clinic profil launch faster
expect clearli launch faster analog in-play share new start switch skyrizi
share sourc busi come non-humira biolog
 skyrizi humira humira leverag say realli seek leverag
humira drive uptak skyrizi skyrizi stand big leverag compon
market seem talk lot
expect decis come week ra file
 interpret lack fda advisori committe said along
expect fda adcom feel comfort clinic profil
page
 might drug launch fast skyrizi would enabl like skyrizi develop
medicin think best class
 agenc like view upacitinib vs jak say product profil clean
appear rule class label cant/wont realli comment
venclexta recent resum mm studi first report
imbruvica new patient share cll
submit uterin fibroid come day
 orlissa approv year yet prior guidanc
achiev say remain take time build market creat patient
awar get enough traction patient make special visit
physician seek drug may modifi current promot strategi physician seem recept
sale lower quarter due lower patient intenational market
disclos recent stop psp trial follow futil analysi alzheim diseas
 opioid litig exposur say liabil
 opioid litig issu ripe enough cant quantifi exposur
realli feel exposur absolut sens reiter problem
 part part exposur sfc propos happi anyth help lower patient
oop cost say oop spend still front-end load patient problem
advoc someth would tri spread patient long road term
final expect extens chang current draft legisl part us part less
 thought intern refer price whether could spread part remind
low part exposur move part would requir legisl action difficult predict
may ultim happen believ sfc good propos hope sort thing
move forward recal discuss refer price wolf comment continu feel
page
strongli intern refer price either part part basi realiti also claim
purport bill work may seek allow us government negoti drug price
negoti tactic view sourc real risk
exhibit show compani report actual result vs estim consensu
exhibit abbvi result vs wr estim consensu
page
exhibit summar financi guidanc vs estim
exhibit abbvi guidanc vs wr estim old new
page
oldnewoldnewtot revenuesgrow op marginapproach sale higher marginjust interest exp approach tax ratejust tax guidancewr estim
exhibit captur chang forecast
exhibit chang wr model agn pro-forma shown bottom
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement oper expens foreign exchang incom expens outstand margin total profit profit profit incom growth oper
page
incom statement oper expens foreign exchang incom expens outstand margin total profit profit profit incom growth oper revenu earli phase total
exhibit wr balanc sheet cash flow statement stand-alon
page
flow statement incom intang chang oper asset flow oper activ busi net cash acquisit properti flow invest activ chang short-term issuanc lt lt debt leas treasuri flow financ activ fx cash increas decreas cash sheet cash properti plant goodwil current term non-curr stock held paid-in comprhens sharehold liabil sharehold
